FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Manickam Aravagiri

Research Profile

Chemicals & Drugs

Disorders

Schizophrenia

Living Beings

Concepts & Ideas

Procedures

Activities & Behaviors

Schizophrenic Psychology

Anatomy

Brain

Co-author Network

Publications

TOP 3
Yan Feng; Bruce G Pollock; Kim Coley; Stephen Marder; Del Miller; Margaret Kirshner; Manickam Aravagiri; Lon S Schneider; Robert R Bies
Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study.
Kristin L Bigos; Bruce G Pollock; Kim C Coley; Del D Miller; Stephen R Marder; Manickam Aravagiri; Margaret A Kirshner; Lon S Schneider; Robert R Bies
Sex, race, and smoking impact olanzapine exposure.
Manickam Aravagiri; Stephen R Marder; Bruce Pollock
Determination of ziprasidone in human plasma by liquid chromatography-electrospray tandem mass spectrometry and its application to plasma level determination in schizophrenia patients.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Manickam Aravagiri (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2008: Yan Feng; Bruce G Pollock; Kim Coley; Stephen Marder; Del Miller; Margaret Kirshner; Manickam Aravagiri; Lon S Schneider; Robert R Bies
Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study.
British journal of clinical pharmacology 2008;66(5):629-39.
2008: Kristin L Bigos; Bruce G Pollock; Kim C Coley; Del D Miller; Stephen R Marder; Manickam Aravagiri; Margaret A Kirshner; Lon S Schneider; Robert R Bies
Sex, race, and smoking impact olanzapine exposure.
Journal of clinical pharmacology 2008;48(2):157-65.
2007: Manickam Aravagiri; Stephen R Marder; Bruce Pollock
Determination of ziprasidone in human plasma by liquid chromatography-electrospray tandem mass spectrometry and its application to plasma level determination in schizophrenia patients.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2007;847(2):237-44.
2006: John D Baird; Luis G Arroyo; Modest Vengust; M Kimberly J McGurrin; Alexander Rodriguez-Palacios; Daniel G Kenney; Manickam Aravagiri; George A Maylin
Adverse extrapyramidal effects in four horse given fluphenazine decanoate.
Journal of the American Veterinary Medical Association 2006;229(1):104-10.
2005: Lawrence J Albers; Vural Ozdemir; Stephen R Marder; Maria Augusta Raggi; Manickam Aravagiri; Laszlo Endrenyi; Christopher Reist
Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy.
Journal of clinical psychopharmacology 2005;25(2):170-4.
2003: Manickam Aravagiri; Stephen R Marder; Keith H Nuechterlein; Michael J Gitlin
Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone.
Therapeutic drug monitoring 2003;25(6):657-64.
2002: Manickam Aravagiri; Stephen R Marder
Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats.
Psychopharmacology 2002;159(4):424-31.
2002: Stephen R Marder; Manickam Aravagiri; William C Wirshing; Donna A Wirshing; M Lebell; Jim Mintz
Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate.
Schizophrenia research 2002;53(1-2):25-30.
2001: Michael J Gitlin; Keith H Nuechterlein; Kenneth L Subotnik; Joseph Ventura; Jim Mintz; David L Fogelson; George Bartzokis; Manickam Aravagiri
Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia.
The American journal of psychiatry 2001;158(11):1835-42.
2000: Manickam Aravagiri; Stephen R Marder
Simultaneous determination of risperidone and 9-hydroxyrisperidone in plasma by liquid chromatography/electrospray tandem mass spectrometry.
Journal of mass spectrometry : JMS 2000;35(6):718-24.
2000: Michael J Gitlin; Keith H Nuechterlein; Jim Mintz; David L Fogelson; George Bartzokis; Joseph Ventura; Kenneth L Subotnik; Manickam Aravagiri
Fluphenazine levels during maintenance treatment of recent-onset schizophrenia: relation to side effects, psychosocial function and depression.
Psychopharmacology 2000;148(4):350-4.
1999: Manickam Aravagiri; Y Teper; Stephen R Marder
Pharmacokinetics and tissue distribution of olanzapine in rats.
Biopharmaceutics & drug disposition 1999;20(8):369-77.
1998: Manickam Aravagiri; A Yuwiler; Stephen R Marder
Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat.
Psychopharmacology 1998;139(4):356-63.
1998: Manickam Aravagiri; Stephen R Marder; Donna A Wirshing; William C Wirshing
Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection.
Pharmacopsychiatry 1998;31(3):102-9.
1997: Manickam Aravagiri; D Ames; William C Wirshing; Stephen R Marder
Plasma level monitoring of olanzapine in patients with schizophrenia: determination by high-performance liquid chromatography with electrochemical detection.
Therapeutic drug monitoring 1997;19(3):307-13.
1995: Ronald E See; A M Lynch; Manickam Aravagiri; Charles Nemeroff; M J Owens
Chronic haloperidol-induced changes in regional dopamine release and metabolism and neurotensin content in rats.
Brain research 1995;704(2):202-9.
1995: Manickam Aravagiri; Stephen R Marder; A Yuwiler; K K Midha; N S Kula; R J Baldessarini
Distribution of fluphenazine and its metabolites in brain regions and other tissues of the rat.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1995;13(3):235-47.
1994: Manickam Aravagiri; Stephen R Marder; T Van Putten; BD Marshall
Simultaneous determination of plasma haloperidol and its metabolite reduced haloperidol by liquid chromatography with electrochemical detection. Plasma levels in schizophrenic patients treated with oral or intramuscular depot haloperidol.
Journal of chromatography. B, Biomedical applications 1994;656(2):373-81.
1994: Robert Paul Liberman; T Van Putten; BD Marshall; Jim Mintz; L Bowen; T G Kuehnel; Manickam Aravagiri; Stephen R Marder
Optimal drug and behavior therapy for treatment-refractory schizophrenic patients.
The American journal of psychiatry 1994;151(5):756-9.
1994: Manickam Aravagiri; Stephen R Marder; T Van Putten; E M Hawes; G McKay; K K Midha
Radioimmunoassay for 7-hydroxy metabolite of fluphenazine and its application to plasma level monitoring in schizophrenic patients treated long term with oral and depot fluphenazine.
Therapeutic drug monitoring 1994;16(1):21-9.
1993: John W Hubbard; Kamal K Midha; Edward M Hawes; Gordon McKay; Stephen R Marder; Manickam Aravagiri; E D Korchinski
Metabolism of phenothiazine and butyrophenone antipsychotic drugs. A review of some recent research findings and clinical implications.
The British journal of psychiatry. Supplement 1993;(22):19-24.
1993: Kamal K Midha; Stephen R Marder; T J Jaworski; Gordon McKay; John W Hubbard; Edward M Hawes; T Van Putten; William C Wirshing; Manickam Aravagiri
Clinical perspectives of some neuroleptics through development and application of their assays.
Therapeutic drug monitoring 1993;15(3):179-89.
1993: Manickam Aravagiri; S R Marder; T Van Putten; K K Midha
Determination of risperidone in plasma by high-performance liquid chromatography with electrochemical detection: application to therapeutic drug monitoring in schizophrenic patients.
Journal of pharmaceutical sciences 1993;82(5):447-9.
1993: T J Jaworski; M S Sardessai; Manickam Aravagiri; G Lin; Y Y Shi; Edward M Hawes; John W Hubbard; Gordon McKay; Kamal K Midha
Synthesis of the N-oxides of phenothiazine antipsychotic agents.
Journal of pharmaceutical sciences 1993;82(3):330-3.
1993: T Van Putten; BD Marshall; R Liberman; Jim Mintz; T G Kuehnel; L Bowen; Manickam Aravagiri; Stephen R Marder
Systematic dosage reduction in treatment-resistant schizophrenic patients.
Psychopharmacology bulletin 1993;29(2):315-20.
1992: Ronald E See; M A Chapman; C E Murray; Manickam Aravagiri
Regional differences in chronic neuroleptic effects on extracellular dopamine activity.
Brain research bulletin 1992;29(3-4):473-8.
1991: Stephen R Marder; K K Midha; T Van Putten; Manickam Aravagiri; E M Hawes; J W Hubbard; G McKay; Jim Mintz
Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response.
The British journal of psychiatry : the journal of mental science 1991;158():658-65.
1991: T Van Putten; Manickam Aravagiri; S R Marder; William C Wirshing; Jim Mintz; N Chabert
Plasma fluphenazine levels and clinical response in newly admitted schizophrenic patients.
Psychopharmacology bulletin 1991;27(2):91-6.
1991: T Van Putten; S R Marder; William C Wirshing; Manickam Aravagiri; N Chabert
Neuroleptic plasma levels.
Schizophrenia bulletin 1991;17(2):197-216.
1990: T Van Putten; S R Marder; William C Wirshing; N Chabert; Manickam Aravagiri
Surreptitious noncompliance with oral fluphenazine in a voluntary inpatient population.
Archives of general psychiatry 1990;47(8):786-7.
1990: Manickam Aravagiri; Stephen R Marder; T Van Putten; E M Hawes; G McKay; J W Hubbard; K K Midha
Therapeutic monitoring of steady-state plasma levels of the N4'-oxide metabolite of fluphenazine in chronically treated schizophrenic patients determined by a specific and sensitive radioimmunoassay.
Therapeutic drug monitoring 1990;12(3):268-76.
1990: Manickam Aravagiri; S R Marder; T van Putten
Determination of plasma homovanillic acid by column liquid chromatography with electrochemical detection.
Journal of chromatography 1990;525(2):419-25.
1990: S R Marder; T Van Putten; Manickam Aravagiri; E M Hawes; J W Hubbard; G McKay; Jim Mintz; K K Midha
Fluphenazine plasma levels and clinical response.
Psychopharmacology bulletin 1990;26(2):256-9.
1989: T Van Putten; S R Marder; Manickam Aravagiri; N Chabert; Jim Mintz
Plasma homovanillic acid as a predictor of response to fluphenazine treatment.
Psychopharmacology bulletin 1989;25(1):89-91.
1989: S R Marder; T Van Putten; Manickam Aravagiri; J W Hubbard; E M Hawes; G McKay; K K Midha
Plasma levels of parent drug and metabolites in patients receiving oral and depot fluphenazine.
Psychopharmacology bulletin 1989;25(3):479-82.
1989: S R Marder; T Van Putten; Manickam Aravagiri
Plasma level monitoring for maintenance neuroleptic therapy.
Psychopharmacology series 1989;7():269-79.
1989: Ronald E See; Manickam Aravagiri; GD Ellison
Chronic neuroleptic treatment in rats produces persisting changes in GABAA and dopamine D-2, but not dopamine D-1 receptors.
Life sciences 1989;44(3):229-36.
1988: Kamal K Midha; Edward M Hawes; John W Hubbard; Gordon McKay; G Rauw; M S Sardessai; Manickam Aravagiri; M D Moore
Radioimmunoassay for fluphenazine sulfoxide in human plasma.
Journal of pharmacological methods 1988;19(1):63-74.